Loading...
ROCO
4171
Market cap35mUSD
Oct 08, Last price  
19.85TWD
1D
7.88%
1Q
16.08%
Jan 2017
40.48%
IPO
-31.46%
Name

GeneReach Biotechnology Corp

Chart & performance

D1W1MN
ROCO:4171 chart
P/E
—
P/S
4.89
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.14%
Rev. gr., 5y
-22.95%
Revenues
233m
+12.71%
365,795,000857,034,0001,012,077,000750,017,000225,460,000206,488,000232,741,000
Net income
-110m
L-7.12%
77,180,000257,284,000376,622,000221,337,000-166,270,000-118,734,000-110,281,000
CFO
-14m
L-40.30%
0169,819,000348,989,000357,633,000-38,673,000-23,224,000-13,864,000
Dividend
Jul 28, 20231.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.

Key people

Baihua Chen
Deputy General Manager - Research and Development Group · since 2025
Pinxing Chou
Senior Deputy General Manager of Operations · since 2025
Shuyu Cao
Head of Accounting · since 2015
Yuyan Fu
Special Assistant to Chairman of the Board · since 2019
Xiuying Zhang
Head of Finance, Corporate Governance Officer · since 2023
Simon Chung
Chief Executive Officer, Director · since 2022
Conghan Liu
Director · since 2019
Leo Liu
Chairman of the Board · since 2013
Jiajun Cai
Independent Director · since 2013
Huiyu Huang
Independent Director · since 2025
Zhiyao Huang
Independent Director · since 2025
Zhufang Luo
Independent Director · since 2022
Yaosheng Ye
Independent Director · since 2019
IPO date
Nov 19, 2012
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT